Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Hepion Pharmaceuticals ( (HEPA) ).
On June 12, 2025, Hepion Pharmaceuticals held its Annual Meeting of Stockholders, where four key proposals were voted on. These included the election of directors, ratification of auditors, approval of a reverse stock split, and an advisory vote on executive compensation. The outcomes of these votes could impact the company’s governance and financial strategies, particularly the reverse stock split, which allows flexibility in managing stock value.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing therapies for liver diseases. The company is engaged in the research and development of treatments targeting chronic liver conditions.
Average Trading Volume: 4,708,755
Technical Sentiment Signal: Strong Sell
Current Market Cap: $792.5K
For an in-depth examination of HEPA stock, go to TipRanks’ Overview page.